---
title: "Genedrive® MT-RNR1 ID Kit Product – Video"
publisher: "Share Talk"
author: "sharetalk"
published: "2022-03-25T12:58:52+00:00"
modified: "2022-03-25T13:05:10+00:00"
date: 2022-03-25
canonical: "https://www.share-talk.com/genedrive-mt-rnr1-id-kit-product-video/"
category: "Exclusive Interviews"
categories: ["Exclusive Interviews", "Healthcare", "Pharmaceutical"]
tags: ["Antibiotic", "biological", "chemistry", "coronavirus", "COVID-19", "COVID19", "David Budd", "diagnostics", "GDR", "Genedrive", "Genedrive Kit", "Genedrive PLC", "hospital", "infectious diseases", "lab testing", "Manchester", "Matthew Fowler", "molecular", "SARS-COV-2", "Share Talk"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# Genedrive® MT-RNR1 ID Kit Product – Video

**Published:** March 25, 2022
**Author:** sharetalk
**Categories:** Exclusive Interviews, Healthcare, Pharmaceutical
**Tags:** Antibiotic, biological, chemistry, coronavirus, COVID-19, COVID19, David Budd, diagnostics, GDR, Genedrive, Genedrive Kit, Genedrive PLC, hospital, infectious diseases, lab testing, Manchester, Matthew Fowler, molecular, SARS-COV-2, Share Talk
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1)

---

**World’s first point of care genetic test used to influence neonatal management in an acute setting and reduce aminoglycoside-induced hearing loss​​**

Prevention – reduces the likelihood of aminoglycoside-induced hearing loss

Rapid results – point-of-care genetic test yields results in 30 minutes

Simple to use – by healthcare professionals with minimal training

**An in vitro diagnostic (IVD) molecular assay for use in human buccal cells**

The Genedrive® MT-RNR1 ID Kit used in conjunction with the Genedrive® System provides an automated result of an individual’s MT-RNR1 m.1555 variant status to inform the clinician ahead of antibiotic treatment decisions. ​

The Genedrive® MT-RNR1 ID Kit is intended to be used by healthcare professionals within a near patient setting.​

The Genedrive® System is a compact benchtop system that provides rapid nucleic amplification, detection and result reporting without the need for data interpretation

- Reduces the likelihood of aminoglycoside induced hearing loss

- Provides a clear patient benefit by informing the clinician ahead of prescription

- Rapid genetic screening prior to aminoglycoside treatment

Individuals with the MT-RNR1 m.1555A>G variant develop profound irreversible hearing loss if exposed to aminoglycoside – population-based studies estimate prevalence of 1:500 (0.2%)

- Single use, cost effective test for use by healthcare professionals with minimal training

- Easy adoption into existing neonatal admissions process to inform clinicians ahead of antibiotic treatment decisions

- Non-invasive test using buccal swabs from the inner cheek

[First NHS Deployments of Genedrive System for AIHL](https://www.share-talk.com/genedrive-plc-aimgdr-first-nhs-deployments-of-genedrive-system-for-aihl/#gs.ukdaze)

![](https://www.share-talk.com/wp-content/uploads/2022/03/Product-Google-Chrome-2022-03-25-at-12.33.03-PM-300x105.jpeg)

 

 

![](https://www.share-talk.com/wp-content/uploads/2022/03/Product-Google-Chrome-2022-03-25-at-12.33.50-PM-300x86.jpeg)

---

**Original URL:** https://www.share-talk.com/genedrive-mt-rnr1-id-kit-product-video/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*